InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
YAR | Ann:Half Yearly Financial Statements - 31 December 2018 (Price Sensitive) | 14/03/19 | 0 | 212 | |||
|
|||||||
YAR | Ann:2018 AGM Results | 02/01/19 | 0 | 476 | |||
|
|||||||
YAR | Ann:Annual Report - 30 June 2018 (Price Sensitive) | 26/10/18 | 0 | 429 | |||
|
|||||||
YAR | Ann:Notice of Annual General Meeting & Proxy Form | 09/10/18 | 0 | 447 | |||
|
|||||||
YAR | Ann:Audited Financial Statements - 30 June 2018 (Price Sensitive) | 29/09/18 | 0 | 473 | |||
|
|||||||
YAR | Ann:Preliminary Final Report - 30 June 2018 (Price Sensitive) | 13/09/18 | 0 | 606 | |||
|
|||||||
YAR | Ann:Dividend Notification (Price Sensitive) | 04/04/18 | 0 | 537 | |||
|
|||||||
YAR | Ann:Half Yearly Financial Statements - 31 December 2017 (Price Sensitive) | 14/03/18 | 0 | 569 | |||
|
See All Discussions